José Pablo Leone1, Nancy U Lin2. 1. Department of Medical Oncology, Division of Breast Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave., Boston, MA, 02215, USA. JoseP_Leone@dfci.harvard.edu. 2. Department of Medical Oncology, Division of Breast Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave., Boston, MA, 02215, USA.
Abstract
PURPOSE OF THE REVIEW: Historically, systemic treatment options for patients with breast cancer brain metastases have been very limited. This review focuses on important considerations for systemic therapy as well as ongoing clinical trials evaluating novel agents. RECENT FINDINGS: For patients with hormone receptor-positive brain metastases, endocrine therapy or chemotherapy options can be considered. The role of CDK4/6 inhibitors is being explored in ongoing trials. Patients with HER2-positive disease have a number of treatment options, including ado-trastuzumab emtansine (TDM1) or lapatinib-capecitabine, and there is emerging evidence of the efficacy of neratinib- and tucatinib-based chemotherapy combinations in the CNS. Triple-negative tumors may respond to chemotherapy. Although much progress remains to be made, a number of effective systemic treatment options are emerging, particularly for patients with HER2-positive disease. Ongoing clinical trials will help define the role of novel agents.
PURPOSE OF THE REVIEW: Historically, systemic treatment options for patients with breast cancer brain metastases have been very limited. This review focuses on important considerations for systemic therapy as well as ongoing clinical trials evaluating novel agents. RECENT FINDINGS: For patients with hormone receptor-positive brain metastases, endocrine therapy or chemotherapy options can be considered. The role of CDK4/6 inhibitors is being explored in ongoing trials. Patients with HER2-positive disease have a number of treatment options, including ado-trastuzumab emtansine (TDM1) or lapatinib-capecitabine, and there is emerging evidence of the efficacy of neratinib- and tucatinib-based chemotherapy combinations in the CNS. Triple-negative tumors may respond to chemotherapy. Although much progress remains to be made, a number of effective systemic treatment options are emerging, particularly for patients with HER2-positive disease. Ongoing clinical trials will help define the role of novel agents.
Entities:
Keywords:
Brain metastases; Breast cancer; Chemotherapy; Metastatic breast cancer; Targeted therapies
Authors: V Franciosi; G Cocconi; M Michiara; F Di Costanzo; V Fosser; M Tonato; P Carlini; C Boni; S Di Sarra Journal: Cancer Date: 1999-04-01 Impact factor: 6.860
Authors: Elisabeth Sophie Bergen; Amelie Binter; Angelika Martina Starzer; Gerwin Heller; Barbara Kiesel; Kristina Tendl-Schulz; Zsuzsanna Bago-Horvath; Julia Furtner; Johannes Leitner; Ruth Exner; Florian Fitzal; Karin Dieckmann; Georg Widhalm; Matthias Preusser; Anna Sophie Berghoff; Rupert Bartsch Journal: Ther Adv Med Oncol Date: 2021-04-22 Impact factor: 8.168
Authors: Nicola Cosgrove; Damir Varešlija; Stephen Keelan; Ashuvinee Elangovan; Jennifer M Atkinson; Sinéad Cocchiglia; Fiona T Bane; Vikrant Singh; Simon Furney; Chunling Hu; Jodi M Carter; Steven N Hart; Siddhartha Yadav; Matthew P Goetz; Arnold D K Hill; Steffi Oesterreich; Adrian V Lee; Fergus J Couch; Leonie S Young Journal: Nat Commun Date: 2022-01-26 Impact factor: 14.919
Authors: Alexander F C Hulsbergen; Abdullah M Abunimer; Fidelia Ida; Vasileios K Kavouridis; Logan D Cho; Ishaan A Tewarie; Rania A Mekary; Philippe Schucht; John G Phillips; Joost J C Verhoeff; Marike L D Broekman; Timothy R Smith Journal: Neuro Oncol Date: 2021-12-01 Impact factor: 13.029